Dogwood Q1 net loss $5.0M; Halneuron Phase 2b data due fall 2026

Dogwood Therapeutics, Inc.

Net loss of $5.0M ($0.15 per share) vs $12.2M ($8.45) in Q1 2025; R&D $2.7M, G&A $2.4M.
Cash $13.2M provides runway into Q4 2026; closed $12.5M of a $26.9M financing in Jan 2026.
Halneuron Phase 2b in CINP: 164 enrolled, top-line results expected fall 2026.
SP16 IND approved; Phase 1b in CIPPN funded by NCI, enrollment starts mid-2026.
Announced global partnership for legacy antiviral assets with potential value up to $100M to Dogwood and shareholders.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Dogwood Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $5.0 million, EPS $0.15 basic and diluted net loss per share.

Period: the first quarter ended March 31, 2026
Net income: $5.0 million
EPS: $0.15 basic and diluted net loss per share
Result: reported results

Exact text from the filing

On May 14, 2026, Dogwood Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the first quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-060747

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.